Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_3
2
40%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated1
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 32 (40.0%)

Trials by Status

completed240%
terminated120%
withdrawn120%
not_yet_recruiting120%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingphase_2

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

NCT06973109
terminatedphase_2

Testosterone and Alendronate in Hypogonadal Men

NCT01460654
completedphase_2

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

NCT00297830
withdrawnphase_3

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

NCT01552122
completedphase_3

Osteoporosis Prevention After Heart Transplant

NCT00000412

Clinical Trials (5)

Showing 5 of 5 trials
NCT06973109Phase 2

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

Not Yet Recruiting
NCT01460654Phase 2

Testosterone and Alendronate in Hypogonadal Men

Terminated
NCT00297830Phase 2

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

Completed
NCT01552122Phase 3

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

Withdrawn
NCT00000412Phase 3

Osteoporosis Prevention After Heart Transplant

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5